Fragile X Syndrome and Medical Cannabis: What Research Shows
Short answer · 2 minute read
Fragile X syndrome and medical cannabis meet in research in one narrow place: a CBD gel rubbed on the skin, tested in children and teenagers. No study in people has looked at THC, smoking, vaping, edibles or oils for fragile X. Cannabis does not treat the syndrome itself, and every form, CBD included, can change how a child’s other medicines work, so the first step is a medicine check with a physician.
This guide draws on the published studies listed under sources and labels each one: a trial in children, an open study without placebo, a review, or work in mice and cells. The full review starts at what the research shows.
Fragile X and cannabis at a glance
Studied
One product, in young people
ZYN002, a pharmaceutical CBD gel applied to the skin, in children and teenagers with the full fragile X mutation [1][2].
Applies to any form
Medicines and sleepiness
CBD and THC are handled by liver enzymes such as CYP3A4, the same ones that clear several seizure medicines. Drowsiness can add up with other drugs.
Not studied
Almost everything else
THC, adults with fragile X, girls as a separate group, premutation carriers, and the oils, gummies and flower sold in dispensaries.
The studies, strongest first · Interactions with seizure medicines
When your child has fragile X: anxiety, meltdowns and no approved medicine
Most parents know the pattern before they know the name for it. A birthday party ends with a child under the table, hands over ears. A kind question from a teacher gets no eye contact at all. A change in the bus route sets off an hour of crying, and bedtime stretches past midnight.
None of this is bad parenting or a stubborn child. Fragile X changes how the brain filters sound, touch and new faces, so ordinary days arrive at full volume.
Too much noise, too many people
Crowds, stores and school assemblies can overload the senses. Some children cover their ears, run, or freeze.
Looking away
Avoiding eye contact and hiding from visitors is so typical of fragile X that it became the main outcome of the largest CBD trial.
Meltdowns
Sudden irritability, tantrums and outbursts, often after a change in routine, can wear down a whole household.
Short nights
Trouble falling asleep and early waking are common, and a tired child has a harder day.
Then comes the harder news. There is no medicine approved by the FDA for fragile X itself [3]. Doctors treat one symptom at a time with drugs made for other conditions, and finding the right one is often trial and error. Meanwhile, social media is full of CBD oils promising calmer children, many sold without a clear label or a lab test.
Which situation is yours?
Pick the one closest to you and the guide points you to the parts that answer it.
Your child has a confirmed diagnosis
Start with what the CBD gel trials did and did not show, then with how states treat patients under 18. The interactions section matters most if your child already takes daily medicine.
You are an adult with fragile X, or you look after one
Adults were not part of the CBD trials, so the evidence is borrowed from younger patients. Whether a state program covers the diagnosis depends on its list and on related diagnoses in the records.
You carry the premutation and have tremor or balance problems
This may be FXTAS, a separate condition of carriers. No study has tested cannabis for it, and tremor and balance need a neurologist’s view first.
Seizure medicines, SSRIs or other daily drugs are prescribed
Here the medicine list matters more than the diagnosis. The CBD trials turned away children on several seizure drugs for exactly this reason.
Fragile X is suspected but not confirmed
A single blood test settles it. Developmental delay, autism or a relative with fragile X are the usual reasons to ask for it.
Testing and what the report says · What the CGG number means
What is fragile X syndrome?
Fragile X syndrome is a genetic condition in which one gene on the X chromosome, FMR1, is switched off. That gene normally makes a protein called FMRP, which helps nerve cells build and fine-tune their connections. Without enough FMRP, the brain develops differently, and the result is a range of learning, behavior and physical differences [4].
It is the most common inherited cause of intellectual disability and the most common single-gene cause of autism [5]. The name comes from the way the X chromosome looks under a microscope in some lab preparations: near the tip it seems pinched, almost broken, which is why the condition is also called fragile X chromosome syndrome.
Boys are affected more often and usually more strongly, for a simple reason: they have one X chromosome, girls have two. Pick a group to see how fragile X tends to look in it.
Boys with the full mutation
Most have intellectual disability, from mild to severe, and delays in speech and walking. Anxiety, hyperactivity and avoiding eye contact are common, and many also meet the criteria for autism. Three in four children in the CBD trials were boys [1].
Girls with the full mutation
The second, working X chromosome softens the picture. Many girls have average intelligence or learning difficulties rather than intellectual disability, and shyness, social anxiety and trouble with math are often what families notice. Because the signs are quieter, girls are diagnosed later or not at all [4].
Adults with fragile X
Many adults live with family or in supported housing, and anxiety often remains the hardest part of daily life. Some, especially women and people born before genetic testing was routine, learn their diagnosis only after a child or grandchild is tested.
What causes fragile X syndrome, and how is it inherited?
Fragile X syndrome is caused by a stretch of DNA that repeats too many times. At the start of the FMR1 gene sits a short code, CGG, written over and over. Everyone has some repeats. When the count passes 200, the cell clamps a chemical tag called a methyl group onto the gene, a process called methylation, and the gene goes silent [3][6]. No FMR1 working means little or no FMRP protein.
Between a normal count and a full mutation lies the premutation. People with it make the protein and usually have no fragile X syndrome, but they are carriers, and the repeat can grow when it passes to their children [7].
What does the number on the test report mean?
An FMR1 DNA report gives a CGG repeat count for each X chromosome, usually in a line marked “CGG repeats” or “allele size”. Choose the range your number falls in. Nothing is saved.
Pick the range from the report and the meaning appears here.
Under 45 repeats: normal
For this person
The gene works as it should. This is not fragile X and not a carrier result.
For their children
The count passes on stably.
45 to 54 repeats: intermediate, the gray zone
For this person
No fragile X syndrome and no carrier conditions are expected.
For their children
The count can shift slightly over generations. A genetic counselor can say what it means for a family [7].
55 to 200 repeats: premutation, a carrier
For this person
The gene still works, but carriers have higher risks of their own: FXTAS, FXPOI and FXAND, explained in the carrier section.
For their children
From a mother, the repeat can expand to a full mutation. Ask for genetic counseling before or during a pregnancy.
Over 200 repeats: full mutation
For this person
This is fragile X syndrome, usually with methylation that switches the gene off. The methylation share appears on the report too, and the CBD trial looked at it closely [1].
For their children
A woman with a full mutation can pass it on; a genetic counselor explains the chances.
Mosaic, or the report is hard to read
What it means
Mosaic means some cells carry one size and others another, or some cells are methylated and others are not. People with mosaicism often have milder signs.
What to do
Ask the ordering doctor or a genetic counselor to go through the report line by line, and bring it to any evaluation.
How fragile X passes from parent to child
FMR1 sits on the X chromosome, so fragile X is X-linked: it follows the X from parent to child. It is often described as X-linked dominant with reduced severity in females, because one altered X is enough to cause signs, yet girls are usually less affected. Pick which parent carries the premutation.
Each daughter
1 in 2 chance of receiving the X with the long repeat. If it expands to a full mutation, she may have fragile X, usually milder than a brother.
Each son
1 in 2 chance of receiving that X. If it expands to a full mutation, he has fragile X syndrome.
The longer the mother’s repeat, the more likely it is to expand on the way to a child [7].
Every daughter
Receives his X, so every daughter is a carrier. The repeat rarely grows into a full mutation when it comes from a father.
Every son
Receives his Y chromosome, not his X, so sons do not inherit the premutation.
His daughters’ children face the mother’s pattern in the next generation [7].
Can fragile X syndrome be prevented or detected before birth?
The syndrome itself cannot be prevented once a child has the full mutation, but families can know their odds early. A carrier test before pregnancy shows whether a woman has a premutation. During pregnancy, chorionic villus sampling or amniocentesis can test the baby’s FMR1 gene, and some families use IVF with embryo testing [7]. A genetic counselor walks through these choices without pressure in either direction.
Does the fragile X research speak to your situation?
Thirteen short questions about the diagnosis, the main concern and the medicines already in use. Your answers stay on this page and show what to raise with a physician.
13 questions · about a minute · your answers stay in this browser
Fragile X syndrome features, effects and behavior problems
The effects of fragile X reach learning, behavior and the body. None of the physical features is present in everyone, and in young children they are often subtle [4]:
- A long, narrow face, a prominent forehead and jaw, and large or prominent ears, which often become clearer after puberty.
- Very flexible joints, especially the fingers, and flat feet.
- Soft skin and, in boys after puberty, enlarged testicles (macroorchidism). A large head size (macrocephaly) is reported in some children.
- Low muscle tone in infancy and later milestones for sitting, walking and talking.
Behavior is what shapes daily life. Families describe anxiety in new places, hyperactivity, short attention, hand flapping or rocking, repeating words, sudden outbursts and a strong wish to avoid eye contact, often in a child who is warm and wants company. Researchers score these behaviors with a checklist built for fragile X, the Aberrant Behavior Checklist, Community version, fragile X edition (ABC-C FXS), and that checklist is how the CBD trials measured change.
What do you see at home?
Tap everything you notice. Each one is matched to the scale researchers scored, so you can see which parts of the CBD research speak to your situation.
- Avoids eye contact is scored as social avoidance. It was the main outcome of CONNECT-FX [1] and also fell from the starting score in the open study [2].
- Meltdowns are scored as irritability and, on a parent scale, as tantrums and mood swings. Both changed in the open study, which had no placebo group [2].
- Hand flapping or rocking is scored as stereotypy, repetitive movements, measured in the open study [2].
- Repeating words is scored as inappropriate speech, measured in the open study [2].
- Can’t sit still is scored as hyperactivity; it showed the smallest change on the checklist in the open study [2].
- Anxiety in crowds is scored on separate anxiety scales, a parent rating and a clinician rating (PARS-R), both used in the open study [2].
- Withdrawn, hard to reach is scored as socially unresponsive or lethargic, measured in the open study [2].
Does fragile X syndrome cause autism?
It can. Fragile X is the best-known single-gene cause of autism, though not every child with fragile X is autistic, and the two are not the same diagnosis. In one trial of low-dose sertraline in young children with fragile X, 60% also had an autism diagnosis [8]. The overlap matters for a medical card too, because autism appears on some state lists where fragile X does not.
Fragile X in males and females
Does fragile X syndrome occur more in males? Yes, and it is usually stronger in them, for the reason shown in the boys and girls tabs above. Girls and women can have fragile X too, often with anxiety and learning differences rather than intellectual disability.
How much these scores changed in trials · Autism and medical cannabis
How is fragile X syndrome diagnosed? Testing and the ICD-10 code
Fragile X is diagnosed with a DNA test of the FMR1 gene, done on a blood sample, sometimes a cheek swab. A pediatrician, developmental specialist or geneticist orders it. Chromosome pictures alone are no longer used, because they miss many cases [7].
Who should be tested
Testing is recommended for a child with developmental delay, intellectual disability or autism without another explanation, for anyone with a relative who has fragile X or a premutation, for women with early menopause or fertility problems that are unexplained, and for adults over 50 with a new tremor and balance problems [7]. Some people also ask for a carrier test before pregnancy.
Which test is used
Labs count the CGG repeats with PCR, a method that copies the DNA region, and use Southern blot or methylation PCR to see whether the gene is switched off. Together they tell a normal result from a premutation, a full mutation or mosaicism [7].
Can fragile X syndrome go undiagnosed?
Often. Girls with milder signs, people with mosaicism and adults who grew up before routine testing are the groups most likely to be missed. Many families learn about fragile X only when a second child or a grandchild is tested.
What to keep from the report
Keep the full lab report: the repeat count for each X, the methylation result, the lab name and the date. A physician at a medical card evaluation looks for a confirmed diagnosis in the records, and the CBD trial grouped children by methylation, so that line is worth having at hand [1].
Fragile X syndrome ICD-10 code: Q99.2, “fragile X chromosome” [9]. Carrier conditions such as FXTAS are usually recorded under the symptoms they cause.
Complications, comorbidities and life expectancy
Fragile X often comes with other conditions. Most are treatable once someone looks for them, which is why pediatric guidelines list regular checks [10].
Matters for CBD
Seizures
Seen in about 16% of people with fragile X, usually in childhood [8]. Seizure medicines are where CBD interactions are best documented.
Attention and hyperactivity
Short attention and restlessness are among the most common reasons a child with fragile X takes daily medicine.
Anxiety
Social anxiety, fear of change and panic in crowds, in boys and girls, often lasting into adult life.
Eyes
Strabismus (eyes that do not line up) and near- or farsightedness, which an eye exam picks up early.
Ears
Frequent ear infections in early childhood, which can affect hearing and speech if they keep coming back.
Heart
Mitral valve prolapse, a floppy heart valve, appears in some adults; a doctor listens for a murmur.
Sleep problems, reflux in infancy, flat feet and loose joints round out the list [10]. Seizures deserve the extra attention: the CBD trials admitted children on no more than two seizure medicines, or seizure-free for a year, and excluded several specific seizure drugs [1].
Fragile X syndrome life expectancy
Fragile X is not considered a life-shortening condition, and most people with it are expected to live a typical life span [11]. Health over the years depends more on the conditions above, on safety in everyday life and on access to care than on the syndrome itself.
What doctors check over the years
The American Academy of Pediatrics clinical report on fragile X lists checks by age: development and behavior at every visit, eyes, ears and hearing, heart sounds, joints and feet, sleep, seizures and, as children grow, mood, anxiety and planning for adult life [10]. Families can bring the list to the pediatrician.
Fragile X carriers: FXTAS, FXPOI and other premutation conditions
A fragile X carrier has a premutation: more CGG repeats than usual, but not enough to switch the gene off. Carriers do not have fragile X syndrome. They are often the mothers, grandmothers and grandfathers of a child with it, and they can have health conditions of their own [7]. Pick one to read about it.
FXTAS: fragile X-associated tremor/ataxia syndrome
Who and what
Mostly men, and some women, with a premutation, usually after 50. A tremor when using the hands, unsteady walking (ataxia), falls, and later memory and mood changes. It can be mistaken for Parkinson’s disease.
What is known about cannabis
No study has tested cannabis or CBD for FXTAS; the trials enrolled children with the full mutation. Unsteadiness and drowsiness are exactly the side effects to avoid in someone who already falls.
FXPOI: fragile X-associated primary ovarian insufficiency
Who and what
Women with a premutation whose ovaries slow down early: irregular or missed periods, early menopause, sometimes before 40, and lower fertility [7].
What is known about cannabis
No research links cannabis to FXPOI. For a woman planning a pregnancy, cannabis in any form is a topic to raise with her doctor first.
FXAND: fragile X-associated neuropsychiatric disorders
Who and what
A name for the anxiety, depression, panic and sleep problems that are more common in carriers, often made heavier by the strain of raising a child with fragile X.
What is known about cannabis
Not studied in carriers. Anxiety on its own appears on some state lists, which is a separate route to discuss with a physician.
Whether a carrier condition qualifies · Anxiety and medical cannabis
Can fragile X syndrome be cured or treated? Medication and guidelines
Fragile X syndrome cannot be cured today. It can be treated, and treatment makes a real difference: therapies support learning and speech, and medicines ease single symptoms such as anxiety or hyperactivity. None of the medicines is approved by the FDA specifically for fragile X, so each one is used “off label”, borrowed from another condition [3].
Choose a symptom to see what is usually tried for it.
| Symptom | What is usually tried | What to know |
|---|---|---|
| Anxiety | SSRIs such as sertraline; in young children, studies used a low dose of 2.5 to 5 mg a day [8]. | Some children become restless or agitated on it [8]. |
| Attention and hyperactivity | Stimulants; guanfacine or clonidine (alpha-2 agonists). | Alpha-2 agonists should not be stopped suddenly [8]. |
| Irritability and aggression | Antipsychotics such as aripiprazole or risperidone. | Weight gain is reported in 30% to 60% of people taking them, so weight is watched [8]. |
| Seizures | Antiseizure medicines chosen by a neurologist. | The group where CBD interactions matter most; see interactions. |
| Learning, speech and daily skills | Speech therapy, occupational therapy, behavioral therapy and an Individualized Education Program (IEP) at school. | The base of care at every age, with or without medicine [10]. |
Nothing matches this filter.
Gene therapy and drugs in development
Several targeted treatments aim at what the missing FMRP protein disrupts, rather than at one symptom. Metformin, a diabetes drug, and minocycline, an antibiotic, have been tried; metformin can upset the stomach in up to 20% of people and minocycline in 39.6% of those in the studies reviewed, and minocycline needs periodic liver and ANA blood tests [8]. BPN14770, a drug acting on a memory pathway, was tested in a trial with 30 patients [3]. Gene therapy is still at an early stage, and long-term safety data are limited [3]. None of these is a cure available today.
Fragile X syndrome guidelines
Two documents guide care in the United States: the American Academy of Pediatrics clinical report on health supervision for children and teenagers with fragile X [10], and the consensus treatment documents of the National Fragile X Foundation’s clinical network [11]. Both put therapy, school support and screening for related conditions first.
Could medical cannabis be worth discussing for fragile X?
For some families, yes, as a question to raise with a physician. CBD was studied in fragile X for three targets: social avoidance, anxiety and irritability [1][2]. Those are the symptoms where the research has something to say, and nothing on this page suggests cannabis in place of therapy, school support or prescribed medicine.
The conversation matters most when a child already takes seizure medicine, an SSRI or an antipsychotic, because CBD can change how the body clears those drugs. An adult with fragile X, or a carrier with anxiety, has a different starting point, covered under qualifying conditions.
Why cannabis comes up in fragile X: the endocannabinoid system
Because the brain has its own cannabinoid system, and in mice with fragile X that system works differently. The endocannabinoid system is a set of signaling molecules the body makes, such as 2-AG and anandamide, and the receptors they bind to, CB1 above all on nerve cells. It helps nerve cells turn their own signals up or down.
-
What losing FMRP breaks
Without FMRP, protein-making at the synapse runs unchecked and the balance between calming and exciting signals shifts [8]. In mice, the cell machinery that makes 2-AG comes apart from the receptor that triggers it, so the brake signal arrives weakly [12].
-
What changed in mice in mice
In Fmr1 knockout mice, mostly males, blocking the enzymes that break down 2-AG restored synaptic function and behavior [12]. Other teams saw the opposite approach work too: low doses of rimonabant, a drug that blocks CB1, reversed key changes [13].
-
Why trials used CBD, not THC
CBD does not switch CB1 on the way THC does. It is thought to soften CB1 activity, raise the body’s own endocannabinoids and act on serotonin and GABA receptors, which fits a system that is out of balance in both directions [6].
That both boosting and blocking CB1 helped mice is a warning against the idea that “more cannabinoids is better”. It also explains why no one has tested THC in children with fragile X. One more result points the same way: cannabidivarin (CBDV), a CBD relative, given early prevented behavior problems in fragile X mice but caused changes in ordinary mice, whose endocannabinoid system was working normally [14].
How the mouse studies were done
In the 2012 study, mice received JZL184, a drug that slows 2-AG breakdown, at 16 mg/kg before behavior tests [12]. The CBDV study gave 20 or 100 mg/kg for 35 days in adolescence [14]. A 2026 study gave AM6545, a CB1 blocker that stays mostly outside the brain, at 1 mg/kg for 7 days; memory improved, and a drug that blocks the serotonin 5-HT4 receptor wiped out the benefit, which ties it to serotonin [15]. Mouse doses per kilogram do not convert into a dose for a child, and all of these are animal results only.
What happened when CBD reached children · How the endocannabinoid system works
What the research shows, from strongest to weakest
In short: one randomized trial and two open studies tested a CBD skin gel in children and teenagers with fragile X. The randomized trial found its clearest benefit in a genetic subgroup, a result that still needs confirming. Everything about how cannabinoids act in fragile X comes from mice and cells.
Not all studies carry the same weight. In a randomized trial, chance decides who gets the treatment and who gets a placebo, so a difference between the groups points to the treatment. An open study gives everyone the treatment and compares them with their own starting point, which also captures hope, extra attention and good weeks. A mouse experiment shows a mechanism, nothing more. The table puts each fragile X study on its rung.
| Study | Who and how many | Form and length | What came out | Level |
|---|---|---|---|---|
| CONNECT-FX, 2022 | 212 children and teenagers, average age 9.7, 75% boys [1] | ZYN002 CBD gel on the skin, 250 mg a day up to 35 kg body weight and 500 mg above it, against placebo gel, 12 weeks [1] | Social avoidance improved more on gel than placebo in the 169 children (79.7%) whose FMR1 gene was at least 90% methylated, with a nominal p value of 0.02 [1] | Randomized trial |
| Phase 1/2 open study, 2019 | 20 children and teenagers, 18 finished; average age 10.4, 75% boys [2] | ZYN002 gel, up to 250 mg a day, 12 weeks, no placebo [2] | Scores for social avoidance, anxiety, irritability and hyperactivity fell from the starting point; 85% had a side effect, most of them mild [2] | Open study, no placebo |
| Long-term extension, 2025 | 240 children and teenagers from the earlier trials [16] | ZYN002 gel, on average 28 months [16] | An interim look at safety: the gel was mostly well tolerated; application-site pain in 6.7% [16] | Open extension, safety |
| Reviews, 2012-2024 | No new patients; experts summing up the field [3][6][8][17][18] | Not applicable | Explain why CBD was tried and how targeted treatments are tested; agree that no drug is approved for fragile X | Review |
| Mouse and cell studies, 2012-2026 | Fmr1 knockout mice, mostly male, and nerve cells in dishes [12][13][14][15] | Injections of drugs that raise or block endocannabinoid signals | Several rescued synapses, memory or behavior in mice; a CBD relative harmed ordinary mice [14] | In mice and cells |
What kinds of studies is this evidence built on?
How to read it: one row per type of published study on cannabinoids and fragile X; a longer bar means more studies of that type. The strongest designs come first. Gray bars, marked background, are reviews and work in animals and cells: useful for ideas, unable to show whether a child benefits.
Show as a table
| Design | Studies |
|---|---|
| Randomized trials | 2 |
| Other clinical trials | 4 |
| Systematic reviews | 1 |
| Case reports | 1 |
| Narrative reviews (background) | 7 |
| Animal studies (background) | 23 |
| Cell and lab studies (background) | 3 |
Browse the studies yourself
Each card is one of the papers this guide cites, summed up in a sentence or two. Papers about mechanisms, or about something other than cannabis, stay in the list with a label.
CONNECT-FX: CBD gel against placebo
Twelve weeks of ZYN002 gel; the benefit on social avoidance showed in children with at least 90% methylation, a nominal result [1].
Two years and more on CBD gel
An interim safety report after an average of 28 months: application-site pain in 6.7%, irritability in 1.7% [16].
The first test of CBD gel in fragile X
Behavior and anxiety scores fell from their starting point over 12 weeks; with no placebo group, the size of the drop cannot be credited to the gel alone [2].
State-of-the-art therapies
A survey of targeted drugs, gene therapy and CBD; no medicine is approved for fragile X yet [3].
Why CBD might help
Sets out how CBD could rebalance endocannabinoid signaling, and notes that the trial effect was strongest in fully methylated children [6].
A CB1 blocker and memory in mice
AM6545 for 7 days improved memory in fragile X mice through a serotonin receptor [15].
Early CBDV in fragile X mice
Given in adolescence, cannabidivarin prevented behavior problems in model mice but caused changes in ordinary mice [14].
Two kinds of nerve cells look alike
Without FMRP, the usual difference between two types of striatal nerve cells disappeared [19].
New targeted treatments
Covers sertraline, metformin, minocycline and CBD, with their side effects and the trials behind them [8].
A memory defect that can be treated
Long-term strengthening of synapses was weaker in fragile X mice (16.9% against 52.1% in normal mice), and treating it restored memory [20].
Reward circuits in fragile X mice
A signaling receptor in the brain’s reward area worked differently in fragile X mice [21].
Dream or reality?
Asks why so many treatments that worked in mice failed in people with fragile X [17].
Low-dose CB1 blocker in mice
Small doses of rimonabant reversed key changes in fragile X mice [13].
CB1 signaling that first rises, then fades
In cultured nerve cells without the fragile X gene, CB1 signals were stronger and later blunted, a mixed result [22].
The endocannabinoid complex comes apart
In fragile X mice, 2-AG production lost its link to its trigger; slowing 2-AG breakdown rescued synapses and behavior [12].
Pathological plasticity
Explains how synapses change abnormally in fragile X, the background to every targeted treatment [18].
A forensic case report
Describes one adult with fragile X and intellectual disability in a criminal case; it says nothing about cannabis [23].
No studies of this type are cited here.
How big were the effects, and how to read them
The CBD trials scored behavior with the ABC-C FXS checklist, filled in by a parent or caregiver. Its social avoidance part has just four questions, about things like hiding from people and avoiding eye contact [1]. That was the main outcome of the randomized trial.
Two kinds of number come out of these studies, and they answer different questions. “Better than placebo” compares two groups over the same weeks, so ordinary ups and downs cancel out. “Better than at the start” compares a child with their own earlier score, and part of that change would have happened anyway.
Why a subgroup? Full methylation means the gene is completely silent, so these children make the least FMRP, and a later review found the gel’s effect grew as methylation approached 100% [6]. Looking at a subgroup after the fact can find patterns by chance, so the finding is being tested again in a further trial.
How much did scores change in the open study?
How to read it: each bar is the size of the change from a child’s own starting score after 12 weeks on the gel, as a standardized mean difference (SMD), a way to put different scales on one ruler. A longer bar means a bigger change. There was no placebo group, so no bar shows how much came from the gel itself.
Show as a table
| Scale | Change (SMD) | p value |
|---|---|---|
| ABC-C FXS social avoidance | 1.0 | 0.001 |
| ABC-C FXS stereotypy | 0.99 | 0.001 |
| ABC-C FXS inappropriate speech | 0.87 | 0.01 |
| ABC-C FXS socially unresponsive or lethargic | 0.76 | 0.01 |
| ABC-C FXS irritability | 0.69 | 0.01 |
| ABC-C FXS hyperactivity | 0.58 | 0.02 |
| Parent rating, hyperactivity and impulsivity | 1.1 | 0.001 |
| Parent rating, anxiety | 1.01 | 0.001 |
| Parent rating, tantrums and mood swings | 0.86 | 0.01 |
| PARS-R anxiety severity | 0.98 | 0.001 |
| PedsQL quality of life | 0.77 | 0.05 |
Why the trial gel is not a dispensary product · The limits of these numbers
Trial gel vs. dispensary products: not the same thing
Every result on this page comes from ZYN002, a pharmaceutical CBD gel made for clinical trials. A parent who reads “CBD helped children with fragile X” and buys a CBD oil is moving the result onto a different product. Here is how the two compare.
What it is
ZYN002 trial gel
A pharmaceutical gel of CBD made in a lab and applied to the skin.
Dispensary CBD product
Oils, gummies, capsules, creams, vapes or flower, made from the plant by many different companies.
Who can get it
ZYN002 trial gel
Only people enrolled in a trial. It is investigational: not approved by the FDA and not sold anywhere.
Dispensary CBD product
Patients with a state medical card at licensed dispensaries, under each state’s rules for patients under 18.
What is in it
ZYN002 trial gel
CBD only, with no THC, at a fixed strength.
Dispensary CBD product
CBD with varying amounts of THC, other cannabinoids and terpenes, listed on a lab-tested label.
Dose
ZYN002 trial gel
What the trial used: 250 mg a day for children up to 35 kg, 500 mg above that [1]. A study dose, not advice.
Dispensary CBD product
No studied dose for fragile X. Swallowed or skin-applied CBD reaches the blood in different amounts, so trial milligrams do not translate.
What each form of cannabis avoids and keeps · Medical and recreational products compared
Forms of cannabis and what applies to fragile X
Cannabis is not only something smoked. Products are inhaled, swallowed, held under the tongue or put on the skin, and each route has its own trade-offs. For fragile X, only one route has data in people. Pick a form to see what it avoids and what stays the same.
On the skin: topicals and transdermal gels
What was studied
The only form with data in fragile X: the transdermal ZYN002 gel, designed so CBD passes through the skin into the blood [1].
What it avoids
Smoke and vapor in the airways, and the first pass through the liver that swallowed products go through.
What remains
CBD that reaches the blood still meets liver enzymes and other medicines. Skin irritation and pain where it is applied. Ordinary creams sold as topicals mostly act locally and were not studied.
Smoke and vapor: joints, pipes, vapes, dabbing
What was studied
Nothing in fragile X.
What it avoids
Vaporizers avoid burning plant material; nothing in this group avoids the airways.
What remains
Hot smoke or vapor in the lungs, fast and strong effects, usually with THC. Concentrates for dabbing are very potent. Not a route a physician would choose for a child.
Swallowed: gummies, capsules, drinks, oils by mouth
What was studied
Nothing in fragile X. Oral CBD was used only in mouse work [14].
What it avoids
The airways.
What remains
Everything swallowed passes through the liver first, starts slowly and lasts longer. A second dose taken because nothing happened yet is a common way to take too much. Gummies look like candy to children.
Under the tongue: tinctures, oils, sprays
What was studied
Nothing in fragile X.
What it avoids
The airways, and part of the liver’s first pass if it is held in the mouth.
What remains
Whatever is swallowed acts like an edible. Drops are easy to measure wrongly, and label strength often differs from what is in the bottle.
THC or CBD: the second question
What was studied
Only CBD, with no THC. There are no data on THC in people with fragile X.
What it means
Results for CBD say nothing about THC, and in mice both raising and blocking CB1 signals changed behavior [12][13].
What remains
THC acts on the developing brain, can cause anxiety and confusion, and is the part most likely to make a child sleepy or unwell.
Types of edibles · Smoke around children · Side effects in the trials
Is CBD safe for children with fragile X? Side effects
In the trials, the CBD gel was generally well tolerated, and most side effects were mild. That is a statement about one pharmaceutical gel, used under medical supervision with blood tests, for weeks to a little over two years. Choose a study to see what it recorded.
Application-site pain
6.4% on the gel against 1.0% on placebo over 12 weeks [1].
Colds and coughs
Upper respiratory infections were among the events reported across the trial [1].
Over 28 months
Application-site pain in 6.7% and irritability in 1.7% of 240 young people [16].
Any side effect
85% of the 20 children had at least one side effect; 70% of all events were mild [2].
Blood tests
Researchers checked liver tests, creatinine for the kidneys and the skin where gel went on [16].
The growing brain
No study followed children into adult life, and THC was never tested. Long-term effects on development are unknown.
Nothing matches this filter.
When to stop and call the doctor
- A seizure that is new, longer or more frequent than usual.
- Unusual sleepiness, a child who is hard to wake, or unsteady walking.
- Yellow skin or eyes, dark urine, belly pain or vomiting, which can point to the liver.
- A rash, blistering or swelling where a product was applied.
- Any sign that a child has swallowed a cannabis product meant for an adult: call Poison Control or emergency services.
Drug interactions with common fragile X medicines
Many children with fragile X take a daily medicine, and some take three. CBD and THC are cleared by liver enzymes, CYP3A4 among them, that also clear several of those drugs, so one can raise or lower the level of another. The CBD trials took this seriously: children on certain seizure medicines or on strong CYP3A4 blockers or boosters were not allowed in [1].
What is on your child’s medicine list?
Take the pharmacy printout or the bottle labels and tap everything on it; the matching entries open below. Nothing is saved.
Clobazam, phenobarbital and other seizure medicines trial rule
CONNECT-FX allowed children on up to two seizure medicines, or seizure-free for at least a year, but excluded clobazam, phenobarbital, ethosuximide, felbamate and vigabatrin [1]. CBD can raise blood levels of some of these drugs. The Epidiolex label also warns that liver enzyme rises are more likely when CBD is combined with valproate [24]. A neurologist sees the full list before anything changes.
Sertraline and other SSRIs mechanism
Low-dose sertraline is common in young children with fragile X and can cause restlessness on its own [8]. Several SSRIs are cleared by the same liver enzymes as CBD, so levels may shift. Agitation, sleepiness or a change in mood after starting anything new is worth a call.
Stimulants for attention mechanism
No study here tested stimulants with CBD. THC raises heart rate, as stimulants do, and both can disturb sleep and appetite. Mention the stimulant by name and dose.
Guanfacine or clonidine review
These lower blood pressure and cause drowsiness, which cannabis can add to. They should not be stopped suddenly to make room for something else [8].
Aripiprazole, risperidone and other antipsychotics review
Weight gain is reported in 30% to 60% of people taking them, and weight is checked regularly [8]. Sedation adds up with cannabis, and some are cleared by CYP3A4.
Minocycline or metformin review
Minocycline needs periodic liver and ANA blood tests; metformin is paused during severe illness or surgery [8]. Since CBD is also watched through liver tests, the physician lines up the timing of blood work.
Many medicines at once trial rule
The trials excluded strong blockers and boosters of CYP3A4, a group that includes some antibiotics, antifungals and seizure drugs [1]. The longer the list, the more a pharmacist’s review is worth, including vitamins and herbal products.
Questions for the pharmacist and neurologist
- Which of my child’s medicines share liver enzymes with CBD or THC?
- Which blood tests, such as liver tests, should be done before and after any change?
- Which medicines already cause sleepiness, and what would add to it?
- If something is added, which signs mean stop, and whom do we call?
Who should not use cannabis with fragile X
For some people the honest answer is “not now” or “not at all”. The trials left these groups out, so there is no evidence that cannabis is safe for them.
- Anyone with seizures that are not controlled and no neurologist involved in the decision.
- People with liver disease or abnormal liver tests.
- A woman who is pregnant, breastfeeding or planning a pregnancy, including carriers of the premutation.
- A child given a THC product without a physician’s plan, a measured dose and a named adult in charge.
- Anyone thinking of stopping a prescribed medicine or therapy to try cannabis instead.
“Not now” can change. A medicine adjustment in progress or an untreated problem may push the question back for a while. A physician should say which answer applies and why, so the family knows whether to come back to it.
What science doesn’t know yet
More is unknown than known. The authors of these studies name the same limits again and again:
- The trials enrolled children and teenagers only, so the results may not apply to adults [1].
- Girls, premutation carriers and people with FXTAS were never studied as separate groups.
- The group with less than 90% methylation was small, and the social avoidance scale has only four questions [1].
- Fixed doses by weight band meant children received different amounts per kilogram [1].
- Open studies keep the children who seem to do well, which flatters the results; firm answers wait on randomized trials [16].
- Most mechanism work used male mice only, and the fragile X mouse does not show every human symptom [14][15].
- THC, and every form other than the trial gel, including all dispensary products, has no data in fragile X.
- Long-term safety, including effects on a developing brain, is unknown, and gene therapy has little long-term safety data [3].
Further trials of CBD gel in fragile X have been registered; their status and results are posted on ClinicalTrials.gov [25]. This page will be updated when new results are published, not before.
How to read a headline about CBD and fragile X
- Mice or children? A result in mice is a reason to run a trial, not a reason to change care.
- Was there a placebo group? Families notice change when they hope for it.
- Which product? A pharmaceutical gel is not an oil from a website.
- Whole group or subgroup? A benefit in a subgroup needs a second trial.
- How long? Twelve weeks cannot show what happens over years.
How to talk to your child’s doctor about cannabis
Set expectations first. The research supports, at most, a careful question about one or two symptoms, such as social avoidance or anxiety. Cannabis will not change the syndrome, and nothing already prescribed should stop. The most useful visit has a clear goal, the full medicine list and notes from home. The doctor can be the pediatrician, the neurologist or the geneticist who knows your child.
Keep a two-week diary
Two weeks of short notes say more than any memory of a hard month. One line a day for each of these, matched to what researchers scored:
- Sleep: bedtime, night waking, time up.
- Anxiety: what set it off, how long it lasted, what helped.
- Meltdowns: how many, how long, after what.
- Social contact: eye contact, hiding from visitors, time with others.
- Any new medicine, dose change or side effect, with the date.
What to bring to the appointment
Tap each item once it is ready. Nothing is saved.
Questions for the pediatrician, neurologist or geneticist
- Is there a symptom where CBD is a reasonable question for my child, given the research?
- Which of the current medicines could interact, and which blood tests should come first?
- What would tell us within a few weeks that it helps, or that it does not?
- Which signs mean stop at once?
- Is there a clinical trial my child could join instead?
What to expect
- A careful look at the diagnosis, the medicine list and the diary.
- An honest answer about what the trials showed and for whom.
- A plan with a goal, a check-in date and a stop rule, if anything is tried at all.
What not to expect
- A cure, or a change in learning or development.
- The trial gel itself, which is not available outside trials.
- A dose taken from a study and applied to a dispensary product.
Is fragile X syndrome a qualifying condition for a medical card?
Rarely by name. Each state program publishes its own list of qualifying conditions, and fragile X syndrome almost never appears on it under that name. The usual route runs through a related diagnosis that the list does include, such as seizures, autism or severe anxiety, or through wording that lets the physician certify another serious or debilitating condition. Lists are revised from time to time, so it is the physician, reading your records at the appointment, who matches them to the version your state uses now.
For a patient under 18, programs add their own conditions, and an adult with fragile X or a carrier with FXTAS follows the adult rules of the state. Both are set by each state, which is why your state’s page is where the answer lives.
Rarely listed
Fragile X by name
Uncommon on state lists. The lab report still matters: it confirms the diagnosis behind the symptoms.
Often listed
A related diagnosis
Seizure disorders, autism or anxiety disorders appear on many lists. They must be diagnosed and written in the records.
Depends on the state
Physician discretion
Some programs let the physician certify a condition that is not named, under their own rules.
What else has a doctor diagnosed?
A meltdown is a symptom; autism written in a chart is a diagnosis, and only the second counts. Choose what is already in the records.
Pick a diagnosis to see how it is usually handled.
Seizures or epilepsy. Listed in many programs. Mind the interactions with seizure medicines above. See epilepsy and medical cannabis and seizures.
Autism. Named on several state lists, sometimes with extra rules for children. See autism and medical cannabis.
Anxiety. A route worth checking for adults with fragile X and for carriers with FXAND, where a state names anxiety disorders. See anxiety and medical cannabis.
Sleep problems. A diagnosed sleep disorder is listed in a few programs. See insomnia and medical cannabis.
None of these. A state with a discretion clause may still cover fragile X; one without it may not. The state law pages say which kind yours is.
Medical cannabis rules by state: legal status, limits, taxes, home cultivation
Four rules change most from one state to the next: whether the state has a medical program only or adult-use sales too, how much a patient may buy and hold, whether patients skip part of the cannabis tax, and whether home growing is allowed. For a family with a child, one point comes first: adult-use stores sell only to people 21 and older, so for anyone younger the medical program is the only legal route.
Legal route
With a medical card
Available to patients under 21 where the state allows minor patients, usually through a parent or legal guardian.
Adult use, 21 and older
Closed to anyone under 21, in every state.
Possession limits
With a medical card
Set by the state for the patient; often higher than the adult-use limit, and a registered caregiver usually follows the patient’s limit.
Adult use, 21 and older
The adult-use limit.
Taxes
With a medical card
Often lower; some states drop part of the cannabis tax for patients.
Adult use, 21 and older
The full state and local cannabis tax.
Home cultivation
With a medical card
Allowed in some states, sometimes for a registered caregiver on the patient’s behalf, with a plant limit.
Adult use, 21 and older
Allowed for adults in some states, often with a lower limit.
Exact numbers, and whether a related diagnosis is on the list today, live on each state’s page and are kept current there. The tax side is compared in medical vs recreational cannabis taxes.
States where our physicians see patients. Each state’s page keeps its current condition list, rules for minor patients, possession limits, patient taxes and home-grow rules.
Medical marijuana laws by state · How medical and recreational cannabis differ
When the patient is a child: how state programs handle minors and caregivers
Most people with fragile X who were studied are children, so a parent is usually the one asking. State law decides whether a minor can be a medical cannabis patient at all, and it attaches extra steps when one can. Many programs work through a caregiver: an adult the state registers to buy, hold and give the product for the patient. Who may be one, and how registration works, is set by each state. Pick the case that fits.
The patient is under 18
Where a state allows minor patients, it usually requires a parent or legal guardian to consent and to register as the caregiver, and some states require more than one physician or a specialist’s certification. Documents commonly asked for include the child’s birth certificate or a court order of guardianship, proof of the diagnosis such as the FMR1 report, and the parent’s ID, as your state sets them.
- The caregiver, not the child, buys and stores the product.
- Some forms or THC levels may be limited for minors.
An adult with fragile X who has a legal guardian
The patient is an adult under the program, but if a court has named a guardian for medical decisions, that guardian consents and may register as the caregiver where the state provides for one. Keep the guardianship order ready, because the physician and the state may ask to see it.
An adult who makes their own decisions
Adults with milder fragile X, and carriers with FXTAS or anxiety, apply as any adult patient does. A family member can still help with the paperwork and come to the appointment if the patient wants.
Medical cannabis and minors · The legal age for CBD · Your state’s rules
Renewal and turning 18: what changes for a fragile X patient
Cards expire on a schedule each state sets, and renewing means a new evaluation. For a fragile X patient the renewal that matters most is the one around the 18th birthday, when the patient moves from the minor rules to the adult ones.
-
While under 18
The parent or guardian handles consent and registration as the state requires, and renews before each expiry date.
-
Turning 18
The patient usually becomes an adult patient in the program. If a guardianship for medical decisions is in place, the guardian keeps that role; if not, the young adult signs for themselves. Check whether the state wants a new application rather than a renewal.
-
At each renewal
Bring an updated medicine list, the diary and any new diagnoses. Symptoms and medicines change over a year, and the physician should hear what changed.
Renewing
Book a repeat evaluation before the card expires. Renewal pages by state are in the state lookup, and the medical card FAQ covers common questions.
If the card is lost
Order a duplicate from the state that issued it; keep a photo of the card and the registration number so that step is quick. More in our lost card guide.
School, work, firearms and privacy for fragile X families
A state card makes medical cannabis legal under state law. It does not change federal law, a school district’s policy or an employer’s drug-testing rules. Pick a topic.
School
Some states have laws on giving medical cannabis to a student patient at school, usually by a parent or caregiver, never by staff on their own initiative; many do not, and schools that take federal funds set their own rules. Ask the school nurse and the district in writing, and keep any plan in the child’s IEP or health plan file.
A parent’s job
A card in a child’s name does not cover the parent. If you handle the product as a caregiver, your own employer’s drug-testing policy still applies to you, and handling a product is not the same as using it. Federal jobs and safety-sensitive work follow stricter rules. Your state’s page on laws and regulations covers employment protections.
Firearms
Cannabis remains a controlled substance under federal law. The federal firearms form, ATF Form 4473, asks whether the buyer is an unlawful user of marijuana, and federal law treats state-legal medical use as unlawful for this purpose [26]. That question concerns the card holder; a family with a child patient should weigh it before registering as a caregiver.
Privacy
Notes from the appointment become part of a medical record, and federal HIPAA rules govern who may see it [27]. A school, a coach or a neighbor has no access to the state registry, and the card itself does not name fragile X or any other diagnosis.
How to get a medical card for fragile X online
The evaluation happens from home, so there is nothing to drive to. It takes four steps; only the first two need you at a screen.
-
About 5 minutes
Fill in the short form
Choose your state, list the diagnoses and medicines, and upload the FMR1 report if you have it.
-
About 15 minutes
Meet a physician licensed in your state
One-on-one and online. You and the physician agree on the start time; allow some slack around it, since an earlier patient can run over.
-
In as little as 15 minutes after the appointment, depending on your state
Receive the signed recommendation
If the physician finds it appropriate, the document appears in your account.
-
Timing set by the state
Register with your state program
Some states keep a patient registry; there you file the recommendation with the health department, which sets its own pace.
What to have ready for fragile X: the FMR1 test report, recent notes from the pediatrician or neurologist, and the medicine list with doses. Without a record of the diagnosis, the physician may not be able to confirm a qualifying condition.
Across 250 reviews from patients in the states where we are licensed. We do not sort them by score and do not hide the low ones.
- 150,000+patients evaluated – everyone who has been through an appointment with us, in every state where we are licensed
- Since 2017doing only this: online evaluations for medical cannabis programs, and nothing else on the side
How the whole process works is explained on how the medical card works; the price for your state is shown before you pay, and what happens if no recommendation is issued is in the medical card FAQ. Your appointments live in your appointments page, and a technical problem goes to support in your account.
Who wrote and reviewed this page
This guide was written by the Dr. Weedy editorial team and checked by the Dr. Weedy medical team, physicians licensed in the states where we work; their names and licenses are on our doctors page. The date of the last update and review is shown under the buttons at the top.
How we choose and check sources
- Every research figure carries a citation you can open in the reference list at the end.
- Each study is labeled by type, so a mouse experiment is never presented as a result in children.
- Background papers that are not about cannabis stay in the list and say so.
- Safety, interactions and who should not use cannabis have their own sections.
- Nothing here promises an outcome; that decision belongs to an appointment with a licensed physician.
Spotted something out of date? The feedback form at the end of the page goes to the editors.
Fragile X syndrome and medical cannabis: questions families ask
Can fragile X syndrome be prevented?
Not once a child has the full mutation. Families who know a premutation runs in the family can use carrier testing, genetic counseling and testing during pregnancy or of embryos to know their chances in advance [7].
Can fragile X syndrome go undiagnosed?
Yes, especially in girls, in people with mosaicism and in adults who grew up before routine testing. One DNA test of the FMR1 gene answers the question.
Does fragile X syndrome cause autism?
It is the most common single-gene cause of autism, but not everyone with fragile X is autistic. In one sertraline trial in young children with fragile X, 60% also had autism [8].
Is fragile X X-linked recessive or dominant?
It is X-linked and usually described as dominant with milder effects in females: one altered X can cause signs, but a girl’s second X often softens them [7]. The inheritance tabs show what each parent passes on.
Can fragile X be detected before birth or during pregnancy?
Yes. Chorionic villus sampling or amniocentesis can test the baby’s FMR1 gene, usually offered when the mother is known to carry a premutation [7].
Is the CBD in dispensaries the same as the trial gel?
No. The trial used ZYN002, an investigational pharmaceutical gel for the skin that is not sold anywhere [1]. Dispensary oils, gummies and creams differ in what they contain and in how much CBD reaches the blood, and none has been studied in fragile X.
Does THC help fragile X?
Nobody knows: there are no studies of THC in people with fragile X. Mouse studies found that blocking the receptor THC acts on also helped [13], which argues against assuming more THC is better.
Is delta-8 THC an option for a child?
Delta-8 acts much like ordinary THC, is sold in stores with looser oversight, and its labels may not match the contents. It has never been studied in fragile X and is not something to give a child without a physician. More in what delta-8 is.
Is an online evaluation legitimate?
It is, as long as your state permits telemedicine for this kind of assessment. The doctor you meet is licensed by your own state, the conversation is private, and the document you leave with carries the same legal weight as one written in a clinic. For a patient under 18, each state adds its own conditions.
Can a parent buy at a dispensary for a child patient?
Only where state law allows it, usually after the parent registers as the child’s caregiver with the state program. The details are on your state’s page and in rules for minors.
Does my card work in another state?
Only where the other state recognizes visiting patients, and visitor rules for minor patients can differ from those for adults. Check which states accept out-of-state cards before a trip.
What if the card is lost?
A new copy comes from the state, not from the physician, and the online portal you registered through is usually where you order it. Our guide to a lost medical card covers the details.
How much does it cost, and what if no recommendation is issued?
You see the exact price for your state on screen before paying, and anything the state charges goes to the state. No one can promise approval ahead of time: the physician decides after hearing the history. What happens to the fee in that case is in the medical card FAQ.
When does the signed document arrive?
In as little as 15 minutes after the appointment, depending on your state, in your account. The state card, where there is one, follows the state’s own timeline.
More research on cannabis and fragile X syndrome
This page cites a selection of studies. Our research library holds every study we track on cannabis and fragile X syndrome, from laboratory work to clinical trials, and lets you filter them by cannabinoid, study type and year.
- studies
- 64
- in people
- 26
- clinical trials
- 7
Fragile X syndrome resources: CDC, MedlinePlus, NCBI and research articles
For reliable information beyond cannabis, these are the places clinicians and families use. Each is listed in the references at the end of the page with its address.
CDC
Plain facts on fragile X, how it is found and where families get support [5].
MedlinePlus Genetics
The National Library of Medicine’s summary of the condition, the gene and inheritance [4].
NCBI GeneReviews
The detailed clinical review of FMR1 disorders: repeat sizes, testing, carriers [7].
AAP clinical report
The pediatric guideline for health checks in children and teenagers with fragile X [10].
National Fragile X Foundation
Family support, clinic network and treatment guidance documents [11].
ClinicalTrials.gov
Registered trials of CBD and other treatments in fragile X, with status and results [25].
Latest research on CBD in fragile X
2019
The first open study of CBD gel in 20 children reports falling behavior and anxiety scores, without a placebo group [2].
2022
CONNECT-FX, the randomized trial of 212 children and teenagers, finds its clearest benefit in fully methylated children [1].
2025
An interim report on 240 young people followed for an average of 28 months describes long-term tolerability [16].
2026
A mouse study ties the memory benefit of a CB1 blocker to a serotonin receptor, a new lead for future work [15].
Every study we track, in the research library · Cannabis news
Talk to a licensed physician about fragile X and cannabis
What is known: a pharmaceutical CBD gel was tested in children and teenagers, was mostly well tolerated, and may ease social avoidance in fully methylated children.
What is not: THC, adults, carriers, and any dispensary product. Every form still needs a medicine check.
Four steps, all online; the fee for your state is shown before you pay, and the physician decides whether a recommendation is right.
Share your experience
References
27 sources
- 1. A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). DOI: 10.1186/s11689-022-09466-6 PMID: 36434514
- 2. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. DOI: 10.1186/s11689-019-9277-x PMID: 31370779
- 3. State-of-the-art therapies for fragile X syndrome. DOI: 10.1111/dmcn.15885 PMID: 38385885
- 4. MedlinePlus Genetics, National Library of Medicine. Fragile X syndrome. 2023.
- 5. Centers for Disease Control and Prevention. About Fragile X Syndrome. 2024.
- 6. Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment. DOI: 10.1186/s11689-023-09475-z PMID: 36624400
- 7. NCBI Bookshelf, GeneReviews. FMR1 Disorders. 2019.
- 8. New Targeted Treatments for Fragile X Syndrome. DOI: 10.2174/1573396315666190625110748 PMID: 31241016
- 9. National Center for Health Statistics, CDC. ICD-10-CM classification (Q99.2 Fragile X chromosome). 2026.
- 10. American Academy of Pediatrics, Pediatrics. Health Supervision for Children and Adolescents With Fragile X Syndrome: Clinical Report. 2022.
- 11. National Fragile X Foundation. Fragile X information, clinics and treatment guidelines. 2026.
- 12. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome DOI: 10.1038/ncomms2045 PMID: 23011134
- 13. Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model. DOI: 10.3390/genes7090056 PMID: 27589806
- 14. Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome. DOI: 10.3390/cells12151927 PMID: 37566006
- 15. A serotonergic mechanism is involved in the pro-cognitive effect of AM6545 treatment in a mouse model of fragile X syndrome DOI: 10.1038/s41398-026-04360-4 PMID: 42971989
- 16. Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension study. DOI: 10.1186/s11689-025-09657-x PMID: 41254489
- 17. The Search for an Effective Therapy to Treat Fragile X Syndrome: Dream or Reality? DOI: 10.3389/fnsyn.2017.00015 PMID: 29163124
- 18. Pathological plasticity in fragile X syndrome. DOI: 10.1155/2012/275630 PMID: 22811939
- 19. Investigating cell-specific effects of FMRP deficiency on spiny projection neurons in a mouse model of Fragile X syndrome. DOI: 10.3389/fncel.2023.1146647 PMID: 37323585
- 20. Treating a novel plasticity defect rescues episodic memory in Fragile X model mice. DOI: 10.1038/mp.2017.221 PMID: 29133950
- 21. Muscarinic M1 Receptor Modulation of Synaptic Plasticity in Nucleus Accumbens of Wild-Type and Fragile X Mice. DOI: 10.1021/acschemneuro.7b00398 PMID: 29486555
- 22. Fmr1 deletion enhances and ultimately desensitizes CB(1) signaling in autaptic hippocampal neurons. DOI: 10.1016/j.nbd.2013.04.002 PMID: 23578490
- 23. Homicide, fragile X syndrome, and mental retardation. DOI: 10.1590/1516-4446-2013-1137 PMID: 24402223
- 24. DailyMed, National Library of Medicine. Epidiolex (cannabidiol) prescribing information. 2026.
- 25. ClinicalTrials.gov, National Library of Medicine. Cannabidiol trials in fragile X syndrome. 2026.
- 26. Bureau of Alcohol, Tobacco, Firearms and Explosives. ATF Form 4473, Firearms Transaction Record. 2023.
- 27. U.S. Department of Health and Human Services. The HIPAA Privacy Rule. 2024.















